Influenza Antiviral Use in Patients Hospitalized With Laboratory-Confirmed Influenza in the United States, FluSurv-NET, 2015–2019
Mark W. Tenforde, Charisse N Cummings, Alissa O’Halloran, Gretchen Rothrock, Pam Daily Kirley, Nisha B. Alden, James Meek, Kimberly Yousey‐Hindes, Kyle P. Openo, Evan J. Anderson, Maya Monroe, Sue Kim, Val Tellez Nunez, Melissa McMahon, Chelsea McMullen, Sarah A. Khanlian, Nancy Spina, Alison Muse, Maria Gaitán, Christina B. Felsen, Krista Lung, Eli Shiltz, Melissa Sutton, Ann Thomas, H. Keipp Talbot, William Schaffner, Andrea Price, Ryan Chatelain, Carrie Reed, Shikha Garg
Abstract
From surveillance data of patients hospitalized with laboratory-confirmed influenza in the United States during the 2015-2016 through 2018-2019 seasons, initiation of antiviral treatment increased from 86% to 94%, with increases seen across all age groups. However, 62% started therapy ≥3 days after illness onset, driven by late presentation to care.